Walgreens specialty pharmacy to share its space in San Francisco
SAN FRANCISCO Walgreens plans to share some of the space for its specialty pharmacy in San Francisco’s Castro district with a local museum, according to published reports.
The Bay Area Reporter, a gay and lesbian newspaper, reported Thursday that Walgreens would expand its specialty pharmacy into one-third of a former laundromat next door while leasing the other two-thirds to the GLBT Historical Society for five years at a reduced rent rate. The museum plans to open in June.
According to the article, Walgreens will pay for the remodeling of the space and seek city permits while using its third of the space for infusion therapy. The pharmacy originally had planned to take over the entire space, but the city government declined to give it a permit, and local business had complained that it would give the pharmacy too large a footprint in the neighborhood.
Report: Prescription drug savings sought in Massachusetts
BOSTON Massachusetts is the only state that does not allow the use of coupons to purchase prescription drugs, but some people hope to change that, according to published reports.
The Boston Business Journal reported Tuesday that a group of lawmakers, health officials and members of professional and industry groups rallied to support legislation that would allow the use of discounts from manufacturers and co-pay assistance programs to help pay for drugs.
The newspaper quoted a spokesman for the Massachusetts Independent Pharmacists Association as saying that previous attempts to enable the use of coupons have been blocked by insurance companies that fear profit loss.
AstraZeneca, Rigel get green light for licensing partnership
SOUTH SAN FRANCISCO, Calif. A licensing agreement between AstraZeneca and Rigel Pharmaceuticals for a rheumatoid arthritis treatment has gone into effect, following the expiration of the waiting period required by the Hart-Scott-Rodino Antitrust Improvements Act, Rigel announced Monday.
The expiration of the waiting period makes Rigel eligible for a payment of $100 million from the Anglo-Swedish drug maker, under terms of a deal the two companies entered whereby AstraZeneca will gain development and sales rights to Rigel’s arthritis drug R788 (fostamatinib disodium). The drug recently completed phase 2 clinical trials.
AstraZeneca also will receive exclusive rights to other Rigel drugs, as well as additional uses for R788. Rigel will receive up to $345 million in milestone payments and up to $800 million in royalties.